These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

945 related items for PubMed ID: 27576956

  • 1. Pediatric Crohn's disease, iron deficiency anemia and intravenous iron treatment: a follow-up study.
    Valério de Azevedo S, Maltez C, Lopes AI.
    Scand J Gastroenterol; 2017 Jan; 52(1):29-33. PubMed ID: 27576956
    [Abstract] [Full Text] [Related]

  • 2. TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose.
    Sobrado CW, Cançado RD, Sobrado LF, Frugis MO, Sobrado MF.
    Arq Gastroenterol; 2015 Dec; 52(4):255-9. PubMed ID: 26840464
    [Abstract] [Full Text] [Related]

  • 3. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
    Beigel F, Löhr B, Laubender RP, Tillack C, Schnitzler F, Breiteneicher S, Weidinger M, Göke B, Seiderer J, Ochsenkühn T, Brand S.
    Digestion; 2012 Dec; 85(1):47-54. PubMed ID: 22179489
    [Abstract] [Full Text] [Related]

  • 4. Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice.
    Stein J, Aksan A, Klemm W, Nip K, Weber-Mangal S, Dignass A.
    J Crohns Colitis; 2018 Jun 28; 12(7):826-834. PubMed ID: 29955835
    [Abstract] [Full Text] [Related]

  • 5. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
    Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, Chopey IV, Gutzwiller FS, Riopel L, Gasche C, FERGI Study Group.
    Gastroenterology; 2011 Sep 28; 141(3):846-853.e1-2. PubMed ID: 21699794
    [Abstract] [Full Text] [Related]

  • 6. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
    Geisser P, Rumyantsev V.
    Arzneimittelforschung; 2010 Sep 28; 60(6a):373-85. PubMed ID: 20648929
    [Abstract] [Full Text] [Related]

  • 7. Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron.
    Lichtenstein GR, Onken JE.
    Dig Dis Sci; 2018 Nov 28; 63(11):3009-3019. PubMed ID: 30056562
    [Abstract] [Full Text] [Related]

  • 8. Treatment with Noripurum EV® is effective and safe in pediatric patients with inflammatory bowel disease and iron deficiency anemia.
    Venturieri MO, Komati JTS, Lopes LHC, Sdepanian VL.
    Scand J Gastroenterol; 2019 Feb 28; 54(2):198-204. PubMed ID: 30782036
    [Abstract] [Full Text] [Related]

  • 9. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.
    Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, Sambuelli AM, D'Haens G, Gasche C.
    Am J Gastroenterol; 2008 May 28; 103(5):1182-92. PubMed ID: 18371137
    [Abstract] [Full Text] [Related]

  • 10. Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life.
    Befrits R, Wikman O, Blomquist L, Hjortswang H, Hammarlund P, Bajor A, Klintman D, Blom H.
    Scand J Gastroenterol; 2013 Sep 28; 48(9):1027-32. PubMed ID: 23889159
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of parenteral iron in children with inflammatory bowel disease.
    Papadopoulos M, Patel D, Korologou-Linden R, Goto E, Soondrum K, Fell JME, Epstein J.
    Br J Clin Pharmacol; 2018 Apr 28; 84(4):694-699. PubMed ID: 29266387
    [Abstract] [Full Text] [Related]

  • 12. Randomized Controlled Trial of Intravenous Ferric Carboxymaltose vs Oral Iron to Treat Iron Deficiency Anemia After Variceal Bleed in Patients With Cirrhosis.
    Tabish M, Agarwal S, Gopi S, Rana R, Ahmed S, Gunjan D, Sharma S, Saraya A.
    Am J Gastroenterol; 2024 Oct 01; 119(10):2061-2069. PubMed ID: 38517084
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of high-dose intravenous iron carboxymaltose vs. iron sucrose for treatment of postpartum anemia.
    Pfenniger A, Schuller C, Christoph P, Surbek D.
    J Perinat Med; 2012 Apr 02; 40(4):397-402. PubMed ID: 22752771
    [Abstract] [Full Text] [Related]

  • 14. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
    Toblli JE, Di Gennaro F.
    PLoS One; 2015 Apr 02; 10(4):e0125528. PubMed ID: 25928811
    [Abstract] [Full Text] [Related]

  • 15. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
    Schröder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, Reinshagen M, Schreiber S, Junge U, Schrott M, Stein J.
    Am J Gastroenterol; 2005 Nov 02; 100(11):2503-9. PubMed ID: 16279906
    [Abstract] [Full Text] [Related]

  • 16. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding.
    Mahey R, Kriplani A, Mogili KD, Bhatla N, Kachhawa G, Saxena R.
    Int J Gynaecol Obstet; 2016 Apr 02; 133(1):43-8. PubMed ID: 26868063
    [Abstract] [Full Text] [Related]

  • 17. Correction of Iron Deficiency Anemia With Intravenous Iron Sucrose in Children With Inflammatory Bowel Disease.
    Danko I, Weidkamp M.
    J Pediatr Gastroenterol Nutr; 2016 Nov 02; 63(5):e107-e111. PubMed ID: 27540710
    [Abstract] [Full Text] [Related]

  • 18. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose.
    Christoph P, Schuller C, Studer H, Irion O, De Tejada BM, Surbek D.
    J Perinat Med; 2012 May 13; 40(5):469-74. PubMed ID: 22945271
    [Abstract] [Full Text] [Related]

  • 19. Clinical significance of C-reactive protein levels in predicting responsiveness to iron therapy in patients with inflammatory bowel disease and iron deficiency anemia.
    Iqbal T, Stein J, Sharma N, Kulnigg-Dabsch S, Vel S, Gasche C.
    Dig Dis Sci; 2015 May 13; 60(5):1375-81. PubMed ID: 25501922
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of intravenous ferric carboxymaltose in Japanese patients with iron-deficiency anemia caused by digestive diseases: an open-label, single-arm study.
    Ikuta K, Ito H, Takahashi K, Masaki S, Terauchi M, Suzuki Y.
    Int J Hematol; 2019 Jan 13; 109(1):50-58. PubMed ID: 30194568
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.